The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Danilov D.S.

Klinika psikhiatrii im. S.S. Korsakova;
kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Classification of antipsychotics and it is importance for the choice of treatment (to 60 anniversary of the introduction of neuroleptics)

Authors:

Danilov D.S.

More about the authors

Read: 23564 times


To cite this article:

Danilov DS. Classification of antipsychotics and it is importance for the choice of treatment (to 60 anniversary of the introduction of neuroleptics). S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(10):91‑100. (In Russ.)

Recommended articles:
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Chro­nic traumatic ence­phalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):16-24
Traumatic inju­ries of the rectum and anus in childhood. Piro­gov Russian Journal of Surgery. 2025;(8):62-66
Features of pero­xide-antioxidant imba­lance in patients with rosa­cea and approaches to comprehensive therapy. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):439-444
Burnout syndrome: prevention, treatment and reha­bilitation. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):61-68

References:

  1. Avrutskii G.Ya., Gurovich I.Ya., Gromova V.V. Farmakoterapiya psikhicheskikh zabolevanii. M: Meditsina 1974; 472.
  2. Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol'nykh. M: Meditsina 1988; 528.
  3. Bal'dasarini R.Dzh., Tarazi F.I. Medikamentoznoe lechenie psikhozov i manii. V kn.: Klinicheskaya farmakologiya po Gudmanu i Gilmanu. M: Praktika 2006; 382-411.
  4. Vertogradova O.P., Gofman D.Ya., Kurapova G.M. i dr. Lechenie bol'nykh shizofreniei stelazinom. V sb.: Voprosy psikhofarmakologii. Trudy GNIIPM MZ RSFSR. T. XXXV. M: Gosudarstvennyi nauchno-issledovatel'skii institut psikhiatrii MZ RSFSR 1962; 175-198.
  5. Danilov D.S. Terapiya shizofrenii (atipichnye neiroleptiki i individual'naya organizatsiya lechebnogo protsessa). M: Miklosh 2010; 320.
  6. Danilov D.S., Tyul'pin Yu.G. Lechenie shizofrenii. M: Meditsinskoe informatsionnoe agentstvo 2010; 276.
  7. Dokazatel'naya meditsina (ezhegodnyi spravochnik) (chast' 2). M: Media sfera 2003; 241-272.
  8. Drobizhev M.Yu., Mukhin A.A. Flupentiksol - nazad v budushchee. Eshche odin atipichnyi neiroleptik? Psikhiatriya i psikhofarmakoterapiya 2003; 5: 1: 35-37.
  9. Kaleda V.G. Mesto rispolepta v sovremennoi psikhofarmakoterapii. M: NTsPZ RAMN 2003; 37.
  10. Mosolov S.N. Osnovy psikhofarmakoterapii. M: Vostok 1996; 288.
  11. Mosolov S.N. Kliniko-neirokhimicheskaya klassifikatsiya sovremennykh antipsikhoticheskikh preparatov. Mezhdunarodnyi zhurnal meditsinskoi praktiki 2000; 4: 35-38.
  12. Mosolov S.N. Polveka antipsikhoticheskoi farmakoterapii: osnovnye itogi i novye rubezhi. V kn.: Dofaminovaya teoriya patogeneza shizofrenii. Rukovodstvo dlya vrachei (red. russkoyaz. izdaniya Mosolov S.N.). London, New York: Taylor & Francis 2004; 14-49.
  13. Nevzorova T.A. Znachenie minimal'nykh doz aminazina pri razlichnykh psikhoticheskikh i nevroticheskikh sostoyaniyakh. Trudy I-go Moskovskogo meditsinskogo instituta. T. 15. M 1961; 43-52.
  14. Panteleeva G.P., Bondar' V.V., Bologov P.V. i dr. Osobennosti klinicheskogo deistviya rispolepta konsta pri dlitel'nom lechenii shizofrenicheskikh i shizoaffektivnykh psikhozov. Psikhiatriya 2006; 4-6: 33-45.
  15. Stal S.S. Novye dostizhenie v terapii shizofrenii. V kn.: Shizofreniya. Izuchenie spektra psikhozov (red. Ancill R.J., Holliday S., Higenbottam J.). M: Meditsina 2001; 154-170.
  16. Costall B., Naylor R.J. Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 1975; 43: 1: 69-74.
  17. Falkai P., Wobrock T., Lieberman J. et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World Journal Biological Psychiatry 2005; 6: 3: 132-191.
  18. Gabay M.P. Galactogogues: medications that induce lactation. Journal Human Lactation 2002; 18: 3: 274-279.
  19. Hesslinger B., Walden J., Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry 2001; 34: 1: 25-26.
  20. Janicak P.G., Davis J.M., Presckorn S.H. et al. Printsipy i praktika psikhofarmakoterapii. Kiev: Nika-Tsentr 1999; 728.
  21. Joy C.B., Adams C.E., Lawrie S.M. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Review 2004; Issue 2.
  22. Maguire G.A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. Journal Clinical Psychiatry 2002; 63: 4: 56-62.
  23. Roth B.L., Sheffler D.J., Potkin S.G. Atypical antipsychotic drug actions: unitary or multiple mechanisms for "atypicality"? Clinical Neuroscience Research 2003; 3: 108-117.
  24. Thornley B., Rathbone J., Adams C.E. et al. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Review 2004; Issue 2.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.